William Meury

Crown Laboratories, Inc. provides pharmaceutical and consumer products. Its products include aesthetics, beauty, therapeutic and prescription products. The firm offers contract development, manufacturing, production and packaging servicers. The company was founded by Don Kilday and Jeff Bedard in November 2000 and is headquartered in Johnson City, TN.

Forest Laboratories, Inc. is engaged in the development, manufacture, and sale of branded forms of drug products. Its products include Bystolic, which is used to decrease heart rate and myocardial contractility; Daliresp, which is used to reduce the risk of chronic obstructive pulmonary disease exacerbation; Linzess, which is used in the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation; and Namenda, which is used in the treatment of moderate to severe dementia. The company was founded in 1954 and is headquartered in New York, NY.

Forest Pharmaceuticals, Inc. manufactures, distributes, and sells forest-branded prescription products in the United States and Puerto Rico. The company is headquartered in St. Louis, MO.

The Jed Foundation exists to protect emotional health and prevent suicide for nation's teens and young adults. It develops expert resources and create partnerships. The firm educates and equip students, families and communities. The company was founded in 2000 and is headquartered in New York, NY.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.